bpc-157 news today fda warning unapproved peptide safety risks new drug The FDA has issued clear signals FDA panel backs easier access

Ex Vivo Efficacy : When applied to tracheal aspirate samples from critically ill patients, BromAc treatment resulted in a notable decrease in SARS-CoV-2 RNA genomic copies after 48 hours, suggesting its potential effectiveness in a clinical setting

These data are first evidence that cereulide high producers rapidly oligomerize the precursor depsipeptides followed by subsequent cyclization, whereas less productive strains seem to accumulate NRPS-bound intermediates at the stage of tetradepsipeptides, only slowly converting them to higher oligomers

& Benali, A

Dihexa(PNB-0408), an oligopeptide drug, is an orally active and blood-brain barrier-permeable analog of angiotensin IV